Projects per year
The use of recombinant factor VIIa (rFVIIa) in trauma patients is usually part of rescue therapy when haemorrhage and coagulopathy have not responded to conventional treatment. In this scenario, trauma patients are likely to have one or more components of the a??triad of deatha?? (coagulopathy, acidosis and hypothermia). The aim of this study was to report on the outcome of trauma patients with the a??triad of deatha?? immediately prior to receiving rFVIIa.
- 1 Finished